The U.S. Food and Drug Administration (FDA) just launched CURE ID, an internet-based repository that will allow the clinical community to report experiences treating difficult-to-treat infectious diseases with novel uses of existing FDA-approved drugs through a website, smartphones, or other mobile devices.
The platform enables the crowdsourcing of medical information from healthcare providers to guide potentially life-saving interventions and facilitate the development of new drugs for neglected diseases. The repository is a collaboration between the FDA and the National Center for Advancing Translational Sciences (NCATS), which is part of the National Institutes of Health (NIH).
“The CURE ID application focuses on drugs for infectious diseases lacking adequate treatments, including neglected tropical diseases, emerging infectious threats, and infections caused by antimicrobial-resistant organisms,” said Amy Abernethy, MD, PhD, FDA Principal Deputy Commissioner. “When healthcare professionals directly input their clinical cases into the app, CURE ID allows these real-world experiences to be organized and analyzed much faster, making it easier to spot promising new uses for existing drugs.”
Understand Emerging Tech Trends by Attending ACRP 2020
Join us at the ACRP 2020 annual conference in Seattle, May 1-4, 2020 to learn about emerging technologies and future trends impacting clinical trials. From SaaS to “digital twins” and beyond, the new Technology and Future Trends Track at ACRP 2020 will prepare you for success by helping you understand and maximize technology innovation in clinical research.
FDA hopes CURE ID will serve as a connector among major treatment centers, academics, private practitioners, government facilities, and other healthcare professionals from around the world and ultimately get treatments to patients faster.
The app works by collecting a simple case report form from caregivers about their experience using an approved product for an unapproved use. Healthcare professionals can browse from a collection of cases that have already been documented, including successful and unsuccessful treatments, in addition to viewing relevant clinical trials and those open to enrollment at ClinicalTrials.gov. App users can also participate in a treatment discussion forum where they can engage with fellow providers globally. The FDA plans to reach out to healthcare providers in various disciplines, including infectious and tropical diseases, to encourage them to use the app.
Edited by Michael Causey